Advertisement
Advertisement

TARA

TARA logo

Protara Therapeutics, Inc. Common Stock

3.59
USD
-0.14
-3.63%
Feb 24, 15:58 UTC -5
Closed
exchange

After-Market

3.5

-0.08
-2.37%

Protara Therapeutics, Inc. Common Stock Profile

About

Protara Therapeutics Inc. is committed to identifying and advancing transformative therapies for rare and specialty diseases. The company's portfolio includes, TARA-002, an investigational cell therapy being developed for the treatment of lymphatic malformations, and intravenous Choline Chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. Protara Therapeutics Inc., formerly known as ArTara Therapeutics, is based in NEW YORK, United States.

Info & Links

CEO

Jesse Shefferman

Headquarters

345 PARK AVENUE SOUTH, 3RD FLOOR
NEW YORK, NY 10010, UNITED STATES

Industry

Medical Drugs

Sector

Medical

Website

www.protaratx.com

Auditor

Ernst & Young LLP

Share holders

17

Employees

27

Protara Therapeutics, Inc. Common Stock Statistics

Valuation Measures

Market Capitalization2

72.20M

Enterprise Value

20.45M

Enterprise Value/EBITDA(ttm)

-0.45

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

--

Price to Book(mrq)

1.00

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

0.00%

Operating Margin(ttm)

--

Profit Margin(ttm)

0.00%

Return on Equity(ttm)

-55.96%

Return on Invested Capital(ttm)

-58.01%

Return on Assets(ttm)

-49.06%

Income Statement

Revenue(ttm)

0.00

Revenue Per Share(ttm)

0.00

Gross Profit(ttm)

0.00

EBITDA(ttm)3

-44.99M

Net Income Available to Common(ttm)

-42.05M

Diluted EPS(ttm)

-2.82

Share Statistics

Beta (5Y Monthly)

1.63

52-Week Change

-14.85%

S&P 500 52-Week Change

18.02%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

20.63M

Dividend Yield

0.00%

Float4

18.05M

% Held by Insiders

12.50%

% Held by Institutions

38.13%

Balance Sheet

Total Cash(mrq)

81.50M

Total Cash Per Share(mrq)

3.95

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

9.85%

Quick Ratio(mrq)

9.85%

Book Value Per Share(mrq)

3.96

Cash Flow

Operating Cash Flow Per Share(ytd)

-1.19

Free Cash Flow(ytd)

-26.56M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement